CN119775419A - 降低可溶性免疫受体cd28的方法和组合物 - Google Patents

降低可溶性免疫受体cd28的方法和组合物 Download PDF

Info

Publication number
CN119775419A
CN119775419A CN202411963509.6A CN202411963509A CN119775419A CN 119775419 A CN119775419 A CN 119775419A CN 202411963509 A CN202411963509 A CN 202411963509A CN 119775419 A CN119775419 A CN 119775419A
Authority
CN
China
Prior art keywords
agent
scd28
antibody
mcd28
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411963509.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·哈基姆
D·阿里什凯维兹
D·哈维兹
E·梅琳
Y·萨皮尔
A·舒尔曼
T·本-摩西
I·曼德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bion Biologics
Original Assignee
Bion Biologics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bion Biologics filed Critical Bion Biologics
Publication of CN119775419A publication Critical patent/CN119775419A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202411963509.6A 2018-03-15 2019-03-14 降低可溶性免疫受体cd28的方法和组合物 Pending CN119775419A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862643334P 2018-03-15 2018-03-15
US201862643355P 2018-03-15 2018-03-15
US62/643,334 2018-03-15
US62/643,355 2018-03-15
US201862774254P 2018-12-02 2018-12-02
US62/774,254 2018-12-02
CN201980029648.2A CN112074539B (zh) 2018-03-15 2019-03-14 降低可溶性免疫受体cd28的方法和组合物
PCT/IL2019/050292 WO2019175885A1 (en) 2018-03-15 2019-03-14 Methods and compositions for decreasing soluble immune receptor cd28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980029648.2A Division CN112074539B (zh) 2018-03-15 2019-03-14 降低可溶性免疫受体cd28的方法和组合物

Publications (1)

Publication Number Publication Date
CN119775419A true CN119775419A (zh) 2025-04-08

Family

ID=66182618

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411963509.6A Pending CN119775419A (zh) 2018-03-15 2019-03-14 降低可溶性免疫受体cd28的方法和组合物
CN201980029648.2A Active CN112074539B (zh) 2018-03-15 2019-03-14 降低可溶性免疫受体cd28的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980029648.2A Active CN112074539B (zh) 2018-03-15 2019-03-14 降低可溶性免疫受体cd28的方法和组合物

Country Status (10)

Country Link
US (2) US12139534B2 (https=)
EP (1) EP3765518A1 (https=)
JP (1) JP7691823B2 (https=)
KR (1) KR20200131260A (https=)
CN (2) CN119775419A (https=)
AU (1) AU2019234183B2 (https=)
BR (1) BR112020018279A2 (https=)
CA (1) CA3093647A1 (https=)
IL (1) IL277354B2 (https=)
WO (1) WO2019175885A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019234183B2 (en) 2018-03-15 2025-12-18 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
EP3938397A1 (en) 2019-03-14 2022-01-19 Biond Biologics Ltd. Small shedding blocking agents
CA3130348A1 (en) * 2019-03-14 2020-09-17 Motti HAKIM A method for immunosuppression
WO2021111442A1 (en) 2019-12-02 2021-06-10 Biond Biologics Ltd. Soluble cd28 levels during immunotherapy
JP2023509803A (ja) * 2019-12-02 2023-03-09 ビオンド バイオロジクス リミテッド Ｍｍｐ抑制の使用
US20230221325A1 (en) * 2019-12-02 2023-07-13 Biond Biologics Ltd. Soluble cd28 levels after immunotherapy
CN115515982A (zh) * 2020-03-12 2022-12-23 比昂生物制剂公司 具有增加的稳定性的脱落阻断剂
EP4399229A2 (en) 2021-09-06 2024-07-17 Biond Biologics Ltd. Cd28 shedding blocking agents
EP4499706A2 (en) * 2022-03-31 2025-02-05 Sana Biotechnology, Inc. Cd4-specific antibody constructs and compositions and uses thereof
WO2025149029A1 (zh) * 2024-01-12 2025-07-17 信达生物制药(苏州)有限公司 抗cd28抗体及其用途
WO2025215647A1 (en) 2024-04-11 2025-10-16 Biond Biologics Ltd. Combination cancer treatment with staggered dosing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL148993A0 (en) 2002-04-04 2002-11-10 Yissum Res Dev Co Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
CN100509849C (zh) 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
PE20110385A1 (es) 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
AU2019234183B2 (en) 2018-03-15 2025-12-18 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28

Also Published As

Publication number Publication date
KR20200131260A (ko) 2020-11-23
BR112020018279A2 (pt) 2020-12-29
JP7691823B2 (ja) 2025-06-12
US20240309094A1 (en) 2024-09-19
CN112074539B (zh) 2025-01-24
EP3765518A1 (en) 2021-01-20
CN112074539A (zh) 2020-12-11
WO2019175885A1 (en) 2019-09-19
IL277354A (en) 2020-11-30
US20210047411A1 (en) 2021-02-18
IL277354B1 (en) 2025-03-01
IL277354B2 (en) 2025-07-01
JP2021517152A (ja) 2021-07-15
AU2019234183A1 (en) 2020-10-01
US12139534B2 (en) 2024-11-12
CA3093647A1 (en) 2019-09-19
AU2019234183B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
CN112074539B (zh) 降低可溶性免疫受体cd28的方法和组合物
CN113710704B (zh) 小脱落阻断剂
US12071466B2 (en) Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof
CN114026124A (zh) 抗hvem抗体及其用途
US12612459B2 (en) Methods of identifying agents that block MCD28 cleavage by MMPS
CN115515982A (zh) 具有增加的稳定性的脱落阻断剂
HK40064257A (en) Small shedding blocking agents
WO2026008059A1 (en) Anti-dll3 constructs and uses thereof
WO2024176224A1 (en) Antibodies against hla-e and use thereof
HK40068325A (en) Anti-hvem antibodies and use thereof
CN118541387A (zh) Cd28脱落阻断剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination